List of Excipients in Branded Drug CARBOPROST TROMETHAMINE

Generic Drugs Containing CARBOPROST TROMETHAMINE

Company	Ingredient	NDC	Excipient
Hospira Inc	carboprost tromethamine	0409-0064	BENZYL ALCOHOL
Hospira Inc	carboprost tromethamine	0409-0064	HYDROCHLORIC ACID
Hospira Inc	carboprost tromethamine	0409-0064	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in CARBOPROST TROMETHAMINE?

# Of NDCs	Excipient
21	BENZYL ALCOHOL
17	HYDROCHLORIC ACID
21	SODIUM CHLORIDE

Carboprost Tromethamine Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

Carboprost tromethamine is an established prostaglandin F2α analogue marketed primarily as a sterile injectable for postpartum hemorrhage and pregnancy termination. Its commercial opportunity is concentrated in supply reliability, preservative-free single-dose presentation, container-closure performance, global registration, and hospital-contract access rather than novel active-ingredient chemistry. The main formulation challenge is maintaining potency and sterility in a low-dose aqueous injection while minimizing excipient burden and avoiding components that complicate neonatal, obstetric, or regulatory review.

What is carboprost tromethamine used for?

Carboprost tromethamine injection is indicated for:

• Control of postpartum hemorrhage caused by uterine atony that has not responded adequately to conventional management
• Second-trimester termination of pregnancy
• Evacuation of uterine contents after fetal loss or failed expulsion

The U.S. reference product is Hemabate, labeled as carboprost tromethamine injection equivalent to 250 micrograms of carboprost per milliliter. The drug is administered intramuscularly or directly into the myometrium, depending on the clinical use and product labeling. Its pharmacologic effect is uterine contraction and reduction of uterine bleeding.[1]

Carboprost is not a biologic, so biosimilar substitution rules do not apply. Competition generally proceeds through generic drug pathways, including abbreviated new drug applications, subject to product-specific FDA requirements.

What is the current FDA and Orange Book status of carboprost tromethamine?

Hemabate is an FDA-approved prescription drug marketed as an injectable dosage form. The reference product has historically been associated with Pfizer legacy entities, including Pharmacia & Upjohn. FDA approval information, current marketing status, and patent listings should be confirmed against the current Orange Book and Drugs@FDA records because marketing rights, label holders, and approved presentations can change.[2,3]

FDA regulatory pathway

A competing carboprost tromethamine injection would normally be evaluated as an ANDA if the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. For an injectable solution, the regulatory burden is usually lower than for a complex delivery system because the product does not require a clinical efficacy trial when the ANDA requirements are satisfied.

Key regulatory attributes include:

Attribute	Commercial significance
Dosage form	Sterile injectable solution
Route	Intramuscular and, where labeled, intramyometrial
Strength	Commonly 250 mcg/mL
Active moiety	Carboprost
Salt form	Carboprost tromethamine
Product category	Small-molecule generic
Biosimilar pathway	Not applicable
Primary regulatory risk	Sterility, potency, stability, extractables, and supply continuity

The applicant must match the reference product’s active ingredient, strength, dosage form, route of administration, and relevant pharmaceutical characteristics. Differences in inactive ingredients may be acceptable, but the applicant must establish that the difference does not affect safety or efficacy.

What excipients are used in carboprost tromethamine injection?

The reference formulation is a low-excipient aqueous injectable. Public labeling identifies carboprost tromethamine as the active ingredient and includes sodium chloride among the formulation components. The product is supplied as a sterile solution in a single-dose container.[1]

A commercial formulation program should treat the following as the principal excipient and presentation variables:

Formulation variable	Function	Development issue
Water for injection	Vehicle	Must support sterility and chemical stability
Sodium chloride	Tonicity adjustment	Concentration must maintain acceptable injection characteristics
Tromethamine	Salt-forming counterion and pH control	Affects solubility, pH, and stability
Container-closure system	Product protection	Must control adsorption, leachables, and oxygen exposure
Nitrogen or other headspace control	Oxidation management, if used	Requires process and container validation
Preservative	Microbial control in multidose systems	May be commercially undesirable in obstetric injectables

The formulation strategy should remain conservative. A product that closely matches the reference composition can reduce ANDA questions, compatibility studies, and hospital substitution concerns.

Is a preservative-free presentation commercially attractive?

Yes. A preservative-free, single-dose presentation is commercially attractive because carboprost is used in acute hospital settings where dose preparation, sterility, and rapid administration matter. A preservative-free product also avoids the need to justify repeated-dose exposure to antimicrobial agents.

A multidose format could reduce packaging cost, but it would introduce additional requirements for antimicrobial preservation, in-use stability, puncture durability, and microbial protection. It could also create purchasing resistance in obstetric and operating-room environments. The strongest initial commercial strategy is therefore a single-dose, ready-to-use presentation.

What formulation patents protect carboprost tromethamine?

The commercial value of carboprost tromethamine is unlikely to depend on a broad, active-ingredient patent estate. The original composition and therapeutic use are mature. The relevant intellectual-property analysis should focus on:

1. Formulation patents covering concentration, pH, excipient combinations, or stabilizers
2. Container-closure patents covering specialized syringes, cartridges, or low-adsorption materials
3. Manufacturing patents covering sterile filling, impurity control, or degradation reduction
4. Method-of-use patents covering specific obstetric dosing regimens or administration techniques
5. Packaging and device rights covering emergency-use delivery systems

A current Orange Book review is required to establish whether any listed patents remain enforceable for the specific reference product. FDA patent listings do not capture every potentially relevant patent, particularly patents directed to manufacturing, packaging, device components, or unapproved commercial uses.[2]

Are Paragraph IV challenges relevant?

Paragraph IV certification may be relevant if the reference product has a listed patent that remains in force. A generic applicant could certify that the patent is invalid, unenforceable, or would not be infringed. If no relevant unexpired Orange Book patent remains, the applicant would generally rely on a different certification pathway.

For carboprost tromethamine, the practical patent risk is more likely to arise from product-specific formulation or device claims than from basic composition claims. A Paragraph IV strategy would need to assess:

• The exact listed patent and expiration date
• Whether the patent claims the approved injection or a different presentation
• Whether the proposed formulation practices every claim limitation
• Whether the patent has been litigated or previously challenged
• Whether a settlement restricts launch timing or product design

No reliable conclusion on a current Paragraph IV dispute should be drawn without a live review of FDA listings, USPTO records, and federal court dockets.

When does carboprost tromethamine lose exclusivity?

Carboprost tromethamine is a mature small-molecule product. Its original regulatory exclusivity and foundational composition patents would ordinarily have expired long before the current market. The commercial question is not basic loss of exclusivity but whether residual patents, regulatory obligations, shortage dynamics, or manufacturing barriers limit effective competition.

For a generic applicant, the relevant exclusivity analysis includes:

Exclusivity category	Relevance
New chemical entity exclusivity	Historical only; not expected to remain active
Five-year orphan exclusivity	Not the principal protection for this product
Three-year clinical-investigation exclusivity	Presentation- or indication-specific if granted
Pediatric exclusivity	Must be checked in current FDA records
Patent term extension	Must be checked against listed patents
Unexpired formulation patents	Potentially relevant
REMS restrictions	Product-specific review required
Drug shortage status	Can materially affect market entry economics

The absence of a strong active-ingredient patent does not guarantee an easy launch. Sterile injectable manufacturing capacity can be more difficult to secure than oral solid-dose capacity, and a small market can limit the number of qualified suppliers.

How should a company design the excipient strategy?

The preferred strategy is a reference-aligned formulation with limited excipient variation.

Strategy 1: Reference-matched sterile solution

This is the lowest-risk pathway. The applicant uses the same active salt, concentration, tonicity approach, and broad pH range as the reference product. The benefits are:

• Lower formulation-development complexity
• Easier pharmaceutical-equivalence analysis
• Fewer questions about tolerability
• Better hospital acceptance
• Lower risk of unexpected precipitation or degradation

The disadvantage is limited differentiation. Price, availability, packaging, and service become the main competitive levers.

Strategy 2: Improved stability formulation

A company could pursue enhanced stability through pH optimization, oxygen control, light protection, or a modified container-closure system. The commercial value would depend on proving a meaningful advantage, such as:

• Longer shelf life
• Less cold-chain dependence
• Lower degradation during distribution
• Better resistance to shipping excursions
• Reduced particulate formation
• Improved compatibility with prefilled delivery systems

A stability claim without a clear procurement benefit is unlikely to support a premium.

Strategy 3: Ready-to-use emergency presentation

A prefilled syringe or other ready-to-administer format could reduce preparation time and medication-error risk. The product would require a device, human-factors, extractables, leachables, and combination-product assessment. It could command stronger hospital interest than a conventional vial if it reduces workflow burden.

The principal risks are device patent exposure, higher manufacturing cost, dose accuracy requirements, and the need to validate long-term drug-device compatibility.

Strategy 4: Multidose presentation

A multidose vial could reduce per-dose packaging cost and improve stocking efficiency. Its disadvantages include preservative exposure, repeated access, in-use dating, microbial control, and possible reluctance from hospital pharmacy departments. It is a secondary strategy rather than the preferred first launch.

What manufacturing and IP barriers affect carboprost tromethamine?

The major barriers are operational rather than fundamental chemistry barriers.

Sterile manufacturing

A manufacturer needs validated aseptic processing or terminal sterilization compatible with the product. Process development must control:

• Bioburden and endotoxin
• Particulate matter
• Fill-volume accuracy
• Container-closure integrity
• Degradation products
• Subvisible particles
• Extractables and leachables
• Batch-to-batch potency

Carboprost is administered in acute obstetric situations. Hospitals therefore place significant value on uninterrupted supply and low recall risk.

Raw-material sourcing

The active pharmaceutical ingredient may have limited qualified sources. A company should evaluate:

• Supplier regulatory history
• DMF availability and status
• Impurity profile
• Residual solvents
• Salt-form consistency
• Capacity during shortage events
• Geographic concentration of production

A dual-source strategy for the API and critical packaging components can be more valuable than a marginal excipient innovation.

Container-closure selection

The container should minimize adsorption, chemical interaction, and light or oxygen exposure. Glass vials are familiar to hospitals and regulators, while polymer containers or prefilled syringes may improve usability but create more extensive compatibility work.

Which companies are challenging the carboprost tromethamine market?

Competition is likely to come from:

• Generic injectable manufacturers
• Contract development and manufacturing organizations
• Specialty hospital-product companies
• Regional manufacturers with obstetric injectable portfolios
• Suppliers seeking to enter during shortages

The market is not a biosimilar field and does not require competition from biologics manufacturers. The principal competitive advantage is dependable sterile supply at an acceptable contract price.

Publicly available sources do not establish a complete, current competitor list or reliable market-share ranking for carboprost tromethamine. Product-level revenue data are generally not reported separately by large pharmaceutical companies.

What commercial opportunities exist beyond the standard vial?

The strongest opportunities are product and supply improvements:

1. Ready-to-use prefilled syringe
2. Improved shelf-life formulation
3. Dual-source or regional supply model
4. Hospital-packaged emergency kits
5. Low-waste single-dose presentation
6. International registration using a common formulation
7. Contract manufacturing for markets with limited sterile capacity

A differentiated product must solve a procurement problem. Longer shelf life, fewer preparation steps, lower wastage, and reliable availability are more defensible value propositions than a new excipient with no clinical or operational benefit.

How does carboprost compare with other postpartum hemorrhage products?

Carboprost competes clinically with oxytocin, misoprostol, methylergonovine, and tranexamic acid, although these products differ in mechanism, route, contraindications, and use sequence.

Product	Typical commercial strength	Formulation advantage	Key limitation
Carboprost tromethamine	Sterile injection	Potent uterotonic for acute use	Injection and respiratory contraindication concerns
Oxytocin	Injection or infusion	Familiar hospital use	Requires controlled administration and storage
Misoprostol	Oral, buccal, sublingual, or rectal tablets	Easier distribution and room-temperature handling	Different adverse-effect and dosing profile
Methylergonovine	Injection and oral forms	Established uterotonic option	Hypertension-related restrictions
Tranexamic acid	Sterile injection and oral forms	Antifibrinolytic rather than uterotonic	Different clinical role and timing

Carboprost’s formulation opportunity is strongest where injectable readiness and supply continuity are valued. It is less attractive for settings that prioritize room-temperature oral products or lower-cost tablet distribution.

What litigation and settlement risks should investors monitor?

The main legal risks are likely to involve:

• Orange Book patent challenges
• ANDA litigation over formulation claims
• Device or prefilled-syringe patents
• Trade-secret disputes involving sterile manufacturing
• Supplier and contract-manufacturing agreements
• Product-liability exposure from dosing or administration errors
• Antitrust or supply-contract issues in shortage conditions

No current settlement terms should be assumed without reviewing the relevant court docket and agreement. A settlement could permit an authorized generic, restrict a formulation, or delay launch despite the absence of a basic composition patent.

Key Takeaways

• Carboprost tromethamine is a mature sterile injectable with limited value in new active-ingredient chemistry.
• The preferred excipient strategy is a simple, reference-aligned, preservative-free aqueous solution.
• Commercial differentiation is more likely through shelf life, packaging, ready-to-use delivery, and supply reliability.
• The most important technical risks are sterility, degradation, container compatibility, and API sourcing.
• Biosimilar competition is not relevant because carboprost is a small-molecule drug.
• Current Orange Book listings, Paragraph IV activity, litigation, and exclusivity dates require verification against live FDA, USPTO, and court records.
• The strongest commercial opportunity is a reliable generic or ready-to-use injectable for hospitals and emergency obstetric care.

FAQs

Can carboprost tromethamine be reformulated with a different buffer?

Potentially, but the applicant must establish pharmaceutical equivalence, stability, compatibility, and lack of clinically meaningful impact from the excipient change. A different buffer can alter pH, degradation, solubility, and injection tolerability.

Is a prefilled carboprost syringe patentable?

A prefilled syringe may support patent protection if the claims cover a novel combination of formulation, device, dose configuration, storage condition, or administration method. Patentability depends on the specific claim structure and prior art.

Does carboprost tromethamine require cold-chain distribution?

Storage requirements depend on the approved product label and stability data. A formulation with demonstrated room-temperature stability could create a commercial advantage, but the claim must be supported by validated long-term and accelerated studies.

What is the most important excipient risk in carboprost injection?

The primary risk is interaction between the formulation and the container-closure system, including adsorption, leachables, extractables, and degradation. The risk is amplified by the low drug concentration and sterile injectable route.

Could a carboprost combination product receive premium pricing?

Potentially, if the combination product reduces administration time, medication errors, waste, or supply burden. A premium is difficult to sustain when the product does not provide a measurable hospital-workflow or clinical advantage.

References

1. Pfizer Inc. (n.d.). Hemabate carboprost tromethamine injection prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and ANDA approval requirements. FDA.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. USP Convention.